<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087646</url>
  </required_header>
  <id_info>
    <org_study_id>MV17150</org_study_id>
    <nct_id>NCT00087646</nct_id>
  </id_info>
  <brief_title>REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy</brief_title>
  <official_title>A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 4 arm study is designed for patients with CHC who have not responded to peginterferon
      alfa-2b (12KD)/ribavirin combination therapy. In these patients, the effects of lengthening
      the duration of treatment, as well as including an initial 12-week period of high-dose
      PEGASYS (360 micrograms sc), are compared with the standard combination therapy of PEGASYS
      (180 micrograms sc) and ribavirin (1000-1200mg po). The anticipated time on study treatment
      is 1-2 years and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Virological Response Rate</measure>
    <time_frame>Up to 72 weeks (Group A) and 48 weeks (Group D)</time_frame>
    <description>Sustained Virological Response (SVR) was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Virological Response (Groups A + B vs Groups C + D)</measure>
    <time_frame>At Week 48 and Week 72</time_frame>
    <description>SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Virological Response (Groups A + C vs Groups B + D)</measure>
    <time_frame>At Week 48 and Week 72</time_frame>
    <description>SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Undetectable HCV-RNA</measure>
    <time_frame>At Week 12, 24, 48 and EOT</time_frame>
    <description>The percentage of participants with a undetectable HCV RNA 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 IU/mL measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end) are reported.
End-of-treatment (EOT) virological response is defined as last HCV RNA measurement that is not detectable (&lt;50 IU/mL) at study day of last dose of study medication (+/- 28 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With &gt;=2log Drop in HCV-RNA</measure>
    <time_frame>At Week 12 and 24</time_frame>
    <description>Reduction in HCV-RNA titers of at least 2 log10 after 12/24 weeks of study treatment (i.e. 99% reduction of viral load) was analyzed. Percentage of participants with at least a 2 log10 drop of HCV-RNA at study week 12 and 24 (lower limit of quantitation 600 IU/mL) as compared to baseline or non-detectable HCV-RNA (lower limit of detection 50 IU/mL) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reduction of HCV Viremia (Groups A + B vs Groups C + D)</measure>
    <time_frame>At Week 12 and 24</time_frame>
    <description>The mean change from baseline in HCV RNA level (reduction in viral load) at Week 12 and 24 were determined. HCV RNA result were not detectable (&lt;50 IU/ML) and not quantifiable (&lt;600 IU/ML). Baseline value were assessed on Day 1 before the administration of the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Maintenance of Actual End-of-Treatment Virological Response</measure>
    <time_frame>Week 96 (Group A and C) and Week 72 (Group B and D)</time_frame>
    <description>Maintenance of end-of-treatment virological response was assessed based on all participants treated and according to the actual treatment period (backward imputation method). The percentage of participants who maintained their end-of-treatment virological response was determined. Maintenance of actual end-of-treatment virological response was calculated by dividing the number of participants with a virological response both at the end of the actual untreated follow-up period and at the end of the actual treatment period by the number of participants with a virological response at the actual end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Relapse After End of Treatment</measure>
    <time_frame>Week 96 (Group A and C) and Week 72 (Group B and D)</time_frame>
    <description>The percentage of participants who relapsed (loss of response) after having achieved a virological response at the end of treatment was determined.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">948</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1000/1200mg po daily for 72 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1000/1200mg po daily for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 micrograms sc weekly for 72 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 micrograms sc weekly for 48 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients &gt;=18 years of age;

          -  CHC infection;

          -  liver biopsy (in &lt;24 calendar months of first dose), with results consistent with CHC
             infection;

          -  use of 2 forms of contraception during study and 6 months after the study in both men
             and women;

          -  Lack of response to previous treatment with peginterferon alfa-2b (12KD)/ribavirin
             combination therapy given for &gt;=12 weeks.

        Exclusion Criteria:

          -  women who are pregnant or breastfeeding;

          -  male partners of women who are pregnant;

          -  conditions associated with decompensated liver disease;

          -  other forms of liver disease, including liver cancer;

          -  human immunodeficiency virus infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ukiah</city>
        <state>California</state>
        <zip>95482</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404-4565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604-3200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20270-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69288</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt Am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg/saar</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oberhausen</city>
        <zip>46145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>10552</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1150-314</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <zip>18003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goeteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddinge</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>81190</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19380853</url>
    <description>This is a full publication titled Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon- alfa2b, A Randomized Trial</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2004</study_first_submitted>
  <study_first_submitted_qc>July 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2004</study_first_posted>
  <results_first_submitted>December 10, 2015</results_first_submitted>
  <results_first_submitted_qc>December 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2016</results_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from 16 September 2003 to 27 February 2007. Participants were recruited over a total of 106 centers [(United States (37), Germany (19), Spain (10), France (9), Italy (7), Greece (5), Turkey (4), Belgium (3), Canada (3), Portugal (3), Sweden (3), Brazil (1), Switzerland (1), and UK (1)] in the study.</recruitment_details>
      <pre_assignment_details>A total of 950 participants were randomized (318, 158, 158, and 316 in groups A, B, C, and D, respectively), 942 received the study medication. A total of 8 randomized participants did not receive study drug for various reasons which includes withdrew consent (5), violated the study entry criteria (1), and two had other protocol violations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Group D</title>
          <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="156"/>
                <participants group_id="P4" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment/Did Not Cooperate</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Selection Criteria at Entry</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat analysis population (ITT) included, all participants randomized who received at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="317"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="156"/>
            <count group_id="B4" value="313"/>
            <count group_id="B5" value="942"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="8.73"/>
                    <measurement group_id="B2" value="48.8" spread="9.93"/>
                    <measurement group_id="B3" value="49.4" spread="8.46"/>
                    <measurement group_id="B4" value="48.5" spread="8.97"/>
                    <measurement group_id="B5" value="48.6" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="212"/>
                    <measurement group_id="B5" value="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Virological Response Rate</title>
        <description>Sustained Virological Response (SVR) was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
        <time_frame>Up to 72 weeks (Group A) and 48 weeks (Group D)</time_frame>
        <population>Intent-to-treat analysis population (ITT) included, all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virological Response Rate</title>
          <description>Sustained Virological Response (SVR) was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
          <population>Intent-to-treat analysis population (ITT) included, all participants randomized who received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group A Vs Group D</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Virological Response (Groups A + B vs Groups C + D)</title>
        <description>SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
        <time_frame>At Week 48 and Week 72</time_frame>
        <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A + Group B</title>
            <description>Group A - Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.
Group B - Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group C + Group D</title>
            <description>Group C - Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.
Group D - Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virological Response (Groups A + B vs Groups C + D)</title>
          <description>SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
          <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
                <count group_id="O2" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9228</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Virological Response (Groups A + C vs Groups B + D)</title>
        <description>SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
        <time_frame>At Week 48 and Week 72</time_frame>
        <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A + Group C</title>
            <description>Group A - Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.
Group C - Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B + Group D</title>
            <description>Group B - Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.
Group D - Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Virological Response (Groups A + C vs Groups B + D)</title>
          <description>SVR was defined as the percentage of participants with a undetectable hepatitis C virus- ribonucleic acid (HCV RNA) 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 International Units Per Millilitre (IU/mL) measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end.</description>
          <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
                <count group_id="O2" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>3.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Undetectable HCV-RNA</title>
        <description>The percentage of participants with a undetectable HCV RNA 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 IU/mL measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end) are reported.
End-of-treatment (EOT) virological response is defined as last HCV RNA measurement that is not detectable (&lt;50 IU/mL) at study day of last dose of study medication (+/- 28 days).</description>
        <time_frame>At Week 12, 24, 48 and EOT</time_frame>
        <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Undetectable HCV-RNA</title>
          <description>The percentage of participants with a undetectable HCV RNA 24 weeks after the end of the treatment period (defined as a single last HCV RNA &lt; 50 IU/mL measured &gt;= 20 weeks after treatment end, ie, &gt;=140 days after treatment end) are reported.
End-of-treatment (EOT) virological response is defined as last HCV RNA measurement that is not detectable (&lt;50 IU/mL) at study day of last dose of study medication (+/- 28 days).</description>
          <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1955</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0883</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With &gt;=2log Drop in HCV-RNA</title>
        <description>Reduction in HCV-RNA titers of at least 2 log10 after 12/24 weeks of study treatment (i.e. 99% reduction of viral load) was analyzed. Percentage of participants with at least a 2 log10 drop of HCV-RNA at study week 12 and 24 (lower limit of quantitation 600 IU/mL) as compared to baseline or non-detectable HCV-RNA (lower limit of detection 50 IU/mL) were reported.</description>
        <time_frame>At Week 12 and 24</time_frame>
        <population>ITT population included all the participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group D</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt;=2log Drop in HCV-RNA</title>
          <description>Reduction in HCV-RNA titers of at least 2 log10 after 12/24 weeks of study treatment (i.e. 99% reduction of viral load) was analyzed. Percentage of participants with at least a 2 log10 drop of HCV-RNA at study week 12 and 24 (lower limit of quantitation 600 IU/mL) as compared to baseline or non-detectable HCV-RNA (lower limit of detection 50 IU/mL) were reported.</description>
          <population>ITT population included all the participants randomized who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Groups A vs Groups D (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.67</ci_lower_limit>
            <ci_upper_limit>3.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Groups A vs Groups D (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3389</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Reduction of HCV Viremia (Groups A + B vs Groups C + D)</title>
        <description>The mean change from baseline in HCV RNA level (reduction in viral load) at Week 12 and 24 were determined. HCV RNA result were not detectable (&lt;50 IU/ML) and not quantifiable (&lt;600 IU/ML). Baseline value were assessed on Day 1 before the administration of the first dose of study drug.</description>
        <time_frame>At Week 12 and 24</time_frame>
        <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A + Group B</title>
            <description>Group A - Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.
Group B - Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group C + Group D</title>
            <description>Group C - Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.
Group D - Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reduction of HCV Viremia (Groups A + B vs Groups C + D)</title>
          <description>The mean change from baseline in HCV RNA level (reduction in viral load) at Week 12 and 24 were determined. HCV RNA result were not detectable (&lt;50 IU/ML) and not quantifiable (&lt;600 IU/ML). Baseline value were assessed on Day 1 before the administration of the first dose of study drug.</description>
          <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
          <units>IU/ML</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="473"/>
                <count group_id="O2" value="469"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HCV RNA Change from BL to Week 12 (n= 424, 421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-2.89" upper_limit="-2.61"/>
                    <measurement group_id="O2" value="-2.18" lower_limit="-2.32" upper_limit="-2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV RNA Change from BL to Week 24 (n= 390, 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" lower_limit="-3.05" upper_limit="-2.70"/>
                    <measurement group_id="O2" value="-2.64" lower_limit="-2.81" upper_limit="-2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Maintenance of Actual End-of-Treatment Virological Response</title>
        <description>Maintenance of end-of-treatment virological response was assessed based on all participants treated and according to the actual treatment period (backward imputation method). The percentage of participants who maintained their end-of-treatment virological response was determined. Maintenance of actual end-of-treatment virological response was calculated by dividing the number of participants with a virological response both at the end of the actual untreated follow-up period and at the end of the actual treatment period by the number of participants with a virological response at the actual end of treatment.</description>
        <time_frame>Week 96 (Group A and C) and Week 72 (Group B and D)</time_frame>
        <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maintenance of Actual End-of-Treatment Virological Response</title>
          <description>Maintenance of end-of-treatment virological response was assessed based on all participants treated and according to the actual treatment period (backward imputation method). The percentage of participants who maintained their end-of-treatment virological response was determined. Maintenance of actual end-of-treatment virological response was calculated by dividing the number of participants with a virological response both at the end of the actual untreated follow-up period and at the end of the actual treatment period by the number of participants with a virological response at the actual end of treatment.</description>
          <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Relapse After End of Treatment</title>
        <description>The percentage of participants who relapsed (loss of response) after having achieved a virological response at the end of treatment was determined.</description>
        <time_frame>Week 96 (Group A and C) and Week 72 (Group B and D)</time_frame>
        <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Group D</title>
            <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Relapse After End of Treatment</title>
          <description>The percentage of participants who relapsed (loss of response) after having achieved a virological response at the end of treatment was determined.</description>
          <population>ITT population included all participants randomized who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="317"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 96 (Groups A and C) and 72-week (Groups B and D)</time_frame>
      <desc>Serious adverse events and non-serious adverse events are reported in Safety Analysis Set, which consists of all participants who received at least one dose of study medication and had a safety assessment performed post baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Participants received 360 microgram (mcg) of peginterferon alfa-2a (PEG-IFN alfa-2a) once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 60 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Participants received 360 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 12 weeks, and thereafter 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 36 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 72 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>Participants received 180 mcg of PEG-IFN alfa-2a once weekly plus 1000/1200 mg of ribavirin daily for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal varices Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>General disorders and Administration site conditions</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Infected insect bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Insulin-dependent Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Lymphatic system neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Unspecified Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="150" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="298" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="137" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="123" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="89" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="313"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="317"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="313"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roche Trial Information Hotline</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

